Aug 30, 2021
Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
Aug 26, 2021
Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525
Aug 04, 2021
Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003
Jul 13, 2021
Immutep Quarterly Activities Report
Jul 05, 2021
Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
Jun 21, 2021
Immutep Completes a A$60 Million Placement to Expand its Clinical Development and Manufacturing Program into Late-Stage Settings
Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy
Jun 07, 2021
Immutep Reveals a New anti-LAG-3 Research Program
Jun 04, 2021
Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021
Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021
Jun 02, 2021
Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor
May 31, 2021
Immutep Enters into a New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti
